Effect of a topically applied neutralizing antibody against vascular endothelial growth factor on corneal allograft rejection of rat

Transplantation

Volumn 66, Issue 11, 1998, Pages 1519-1524

  Yatoh, Shigeru ^a   Kawakami, Yasushi ^a   Imai, Masayuki ^b   Kozawa, Tadahiko ^b   Segawa, Toshiaki ^c   Suzuki, Hideo ^c   Yamashita, Kamejiro ^a   Okuda, Yukichi ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b Kozawa Hospital   (Japan)

^c Base Technology Center   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ANGIOGENESIS; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; CORNEA TRANSPLANTATION; GRAFT REJECTION; GRAFT SURVIVAL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; RAT; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ANIMALS; ANTIBODIES; CORNEAL NEOVASCULARIZATION; CORNEAL TRANSPLANTATION; ENDOTHELIAL GROWTH FACTORS; GRAFT REJECTION; LYMPHOKINES; RATS; RATS, INBRED F344; RATS, INBRED LEW; SURVIVAL RATE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0032535523     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199812150-00016     Document Type: Article

References (18)

1. Aldrege OC, Krachmer JH. Clinical types of corneal graft rejection: their manifestations, frequency, preoperative correlates and treatment. Arch Ophthalmol 1981; 99: 599.
2. Lindstrom RL. Advances in corneal transplantation. N Engl J Med 1986; 315: 1.
3. Pleyer U, Steuhl KP, Weidle EG, Lisch W, Thiel HJ. Corneal graft rejection: incidence, manifestation and interaction of clinical subtypes. Transplant Proc 1992; 24: 2034.
4. Rinne JR, Stulting RD. Current practices in the prevention and treatment of corneal graft rejection. Cornea 1992; 11: 326.
5. Belin MW, Bouchard CS, Frantz S, Chmielinska J. Topical cyclosporine in high-risk corneal transplants. Ophthalmology 1989; 96: 1144.
6. Kobayashi C, Kanai A, Nakajima A, Okumura K. Suppression of corneal graft rejection in rabbits by a new immunosuppressive agent, FK-506. Transplant Proc 1989; 21: 3156.
7. Ayliffe W, Alam Y, Bell EB, McLeod D, Hutchinson IV. Prolongation of rat corneal graft survival by treatment with anti-CD4 monoclonal antibody. Br J Ophthalmol 1992; 76: 602.
8. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992; 13: 18.
9. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118: 445.
10. Gill TJ, Kunz HW, Misra DN, Cortese Hassett AL. The major histocompatibility complex of rat. Transplantation 1987; 43: 773.
11. Williams KA, Coster DJ. Penetrating corneal transplantation in the inbred rat: a new model. Invest Ophthalmol Vis Sci 1985; 26: 23.
12. Kondo S, Asano M, Suzuki H. Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth, and its inhibition by the antibody. Biochem Biophys Res Commun 1993; 194 (3): 1234.
13. Callanan D, Peeler J, Niederkorn JY. Characteristics of rejection of orthotopic corneal allografts in the rats. Transplantation 1988; 45: 437.
14. Milani JK, Pleyer U, Dukes A, et al. Prolongation of corneal allograft survival with liposome-encapsulated cyclosporine in the rat eye. Ophthalmology 1993; 100: 890.
15. Asano M, Yukita A, Matsumoto T, Matsuo K, Kondo S, Suzuki H. Isolation and characterization of neutralizing monoclonal antibodies to human vascular endothelial growth factor/vascular permeability factor 121 (VEGF/VPF121). Hybridoma 1995; 14: 475.
16. Sone H, Kawakami Y, Sekine Y, et al. Ocular vascular endothelial growth factor levels in diabetic rats are elevated before observable retinal proliferative changes. Diabetologia 1997; 40: 726-730.
17. Yoshida S, Ono M, Shono T, et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor α-dependent angiogenesis. Mol Cell Biol 1997; 17: 4015.
18. Sunderrotter C, Steinbrink K, Goebeler M, et al. Macrophage and angiogenesis. J Leukemic Biol 1994; 55: 410.